With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
July 7, 2017. Adenoid cystic carcinoma (ACC) is a salivary gland tumor that has notoriously few systemic therapy options available either to enhance radiation or to treat recurrent/metastatic disease. Enter: a translational study in Clinical Cancer Researchwhich evaluated the radiosensitizing effects of MDM2 inhibition in ACC tumor xenografts. Why MDM2 inhibition? ACC is rare among cancers in that <5% of ACC tumors have p53 mutations (a common hallmark of cancer). Functioning MDM2 tags p53 for degradation. So if p53 is intact and you inhibit its inhibitor, the cell should, in theory, arrest when there is DNA damage (i.e., a radiation injury). The combination of MDM2 inhibition during radiation resulted in dramatic tumor responses as theorized. Next up, humans!